N-Desmethyl Bedaquiline-d6 is the deuterium labelled form of N-Desmethyl Bedaquiline.
N-Desmethyl Bedaquiline-d6 is the deuterium-labeled form of N-Desmethyl Bedaquiline, the major circulating metabolite of the antitubercular drug Bedaquiline (Sirturo). It is used as an internal standard for the quantification of N-Desmethyl Bedaquiline in biological matrices for pharmacokinetic and metabolism studies. Target: ATP Synthase (indirectly, as a tracer for metabolite quantification). Bedaquiline and its N-desmethyl metabolite inhibit mycobacterial ATP synthase, targeting subunit c of the enzyme, thereby depleting ATP and killing Mycobacterium tuberculosis. The deuterated standard is a tracer. No direct in vitro activity is reported for the labeled standard. The non-labeled N-Desmethyl Bedaquiline retains moderate antimycobacterial activity against M. tuberculosis but is significantly less potent than parent bedaquiline. No in vivo studies are performed with the labeled compound. However, in animal models, the parent bedaquiline and its metabolites have shown activity against tuberculosis, with N-desmethyl metabolite accumulating in tissues and contributing to the long terminal half-life. For cell-free assays (LC-MS/MS): prepare plasma, tissue homogenates, or urine samples, add N-Desmethyl Bedaquiline-d6 internal standard, perform protein precipitation with acetonitrile or methanol, centrifuge, inject the supernatant onto an LC-MS/MS system. Quantitation is based on analyte/internal standard peak area ratio. No cell-based assays are performed with the deuterated standard. The parent bedaquiline is tested in intracellular macrophage assays for M. tuberculosis growth inhibition. The labeled compound is not used in such assays. No animal studies are conducted with the labeled internal standard itself. For PK studies of unlabeled bedaquiline and its N-desmethyl metabolite, animals (mice, rats, dogs) are dosed orally, serial blood samples are collected, processed with N-Desmethyl Bedaquiline-d6 internal standard, and analyzed by LC-MS/MS to determine PK parameters. PK properties of N-Desmethyl Bedaquiline: It is the major circulating metabolite in humans with an extremely long half-life (up to 5-6 months), extensive tissue distribution, and high plasma protein binding (>99.9%). The deuterated standard does not exhibit distinct PK properties. No toxicity data are reported for N-Desmethyl Bedaquiline-d6. For parent bedaquiline, toxicities include QT prolongation, hepatotoxicity (elevated liver enzymes), and gastrointestinal effects. The N-desmethyl metabolite may contribute to the prolonged safety profile due to its long half-life. N-Desmethyl Bedaquiline-d6 is a research tool and not approved for clinical use. The parent drug Bedaquiline is FDA-approved for the treatment of multidrug-resistant tuberculosis (MDR-TB) as part of combination therapy. This deuterated standard is essential for therapeutic drug monitoring (TDM) and pharmacokinetic studies of bedaquiline and its metabolite in tuberculosis patients.

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.